Morris Naus, MD
Gastroenterology · Delray Beach, FLNPI 1598751679
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $135,082 of the $193,162 with a category attached, or 69.9%. Phathom Pharmaceuticals, Inc. accounts for 61.7% of it on its own, with 45 other manufacturers making up the rest. Reporting peaked in 2024 at $115,415 and has fallen 72.1% since, to $32,180 in 2025. Among gastroenterology clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,035 payments — averaging $186.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Phathom Pharmaceuticals, Inc.$119K
- Celltrion USA Inc.$23K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$22K
- Takeda Pharmaceuticals U.S.A., Inc.$10K
- AbbVie$6K
- Otsuka America Pharmaceutical, Inc.$4K
- plus $10K from 40 others
What the payments were for
- Consulting fees$3,7732%
- Speaking & faculty fees$135,08270%
- Travel & lodging$30,09616%
- Food & beverage$23,75712%
- Education$4560%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$193,162 in reported general payments places this provider in the 95th percentile of 1,388 gastroenterology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XifaxanRifaximin | 33 | $109,174 |
| VoqueznaVonoprazan Fumarate | 104 | $77,066 |
| LinzessLinaclotide | 50 | $42,804 |
| Dexlansoprazole DrDexlansoprazole | 48 | $13,873 |
| ClenpiqSod Picosulf/Mag Ox/Citric Ac | 61 | $10,404 |
| Pantoprazole Sodium | 495 | $9,220 |
| SutabSod Sulf/Pot Chloride/Mag Sulf | 38 | $6,163 |
| Esomeprazole Magnesium | 160 | $5,807 |
| Omeprazole | 270 | $4,534 |
| Ursodiol | 15 | $3,712 |
| Colestipol Hcl | 33 | $2,887 |
| Lubiprostone | 17 | $1,652 |
| SuflavePeg 3350/Sod Sulf,chlr/Pot/Mag | 13 | $1,601 |
| Budesonide DrBudesonide | 13 | $1,505 |
| Dicyclomine Hcl | 53 | $1,129 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $21,849 | $109,17433 claims |
| Phathom Pharmaceuticals, Inc.Voquezna | $119,266 | $77,066104 claims |
| AbbVieLinzess | $5,598 | $42,80450 claims |
| Ferring Pharmaceuticals Inc.Clenpiq | $343 | $10,40461 claims |
| Braintree Laboratories, Inc.Sutab, Suflave | $299 | $7,76451 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,388 gastroenterology providers in Florida.
Other gastroenterology in Delray Beach
- Samuel GidayOrlando$2M
- Lukasz KwapiszMiami$1.2M
- Jennifer Seminerio-DiehlOrlando$1.1M
- Udayakumar NavaneethanSaint Petersburg$1.1M
- Ronen AraiCoral Springs$1.1M
- Charles SninskyGainesville$983K
- Peter DraganovGainesville$832K
- Arin NewmanMiami Beach$716K
- Joanna LopezMiami$670K
- Jose NietoSebring$573K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.